PL3372229T3 - Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana - Google Patents

Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana

Info

Publication number
PL3372229T3
PL3372229T3 PL18169211T PL18169211T PL3372229T3 PL 3372229 T3 PL3372229 T3 PL 3372229T3 PL 18169211 T PL18169211 T PL 18169211T PL 18169211 T PL18169211 T PL 18169211T PL 3372229 T3 PL3372229 T3 PL 3372229T3
Authority
PL
Poland
Prior art keywords
methods
angelman syndrome
tonic inhibition
treating angelman
increasing tonic
Prior art date
Application number
PL18169211T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics, Inc. filed Critical Ovid Therapeutics, Inc.
Publication of PL3372229T3 publication Critical patent/PL3372229T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
PL18169211T 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana PL3372229T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP15803364.7A EP3151832B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
PCT/US2015/034018 WO2015187851A1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating secondary insomnia
EP18169211.2A EP3372229B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating angelman syndrome

Publications (1)

Publication Number Publication Date
PL3372229T3 true PL3372229T3 (pl) 2021-10-04

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15803364T PL3151832T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności
PL18169211T PL3372229T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15803364T PL3151832T3 (pl) 2014-06-06 2015-06-03 Sposoby zwiększenia hamowania tonicznego i leczenia wtórnej bezsenności

Country Status (19)

Country Link
US (10) US20150352085A1 (pl)
EP (3) EP3151832B1 (pl)
JP (4) JP2017516868A (pl)
AR (1) AR100772A1 (pl)
AU (4) AU2015269667B2 (pl)
CA (1) CA2950845C (pl)
CY (2) CY1124366T1 (pl)
DK (2) DK3372229T3 (pl)
ES (2) ES2875742T3 (pl)
HR (2) HRP20210901T1 (pl)
HU (2) HUE055155T2 (pl)
IL (2) IL249287B (pl)
LT (2) LT3372229T (pl)
MX (2) MX2020012404A (pl)
PL (2) PL3151832T3 (pl)
PT (2) PT3372229T (pl)
RS (2) RS62007B1 (pl)
SI (2) SI3151832T1 (pl)
WO (1) WO2015187851A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3151832B1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Methods of increasing tonic inhibition and treating secondary insomnia
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
CA2992734A1 (en) * 2015-07-17 2017-01-26 Ovid Therapeutics, Inc. Methods of treating developmental disorders with gaboxadol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
BR112019002538A2 (pt) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2019028234A1 (en) 2017-08-04 2019-02-07 Ovid Therapeutics Inc. USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
EP3833351A4 (en) 2018-09-20 2021-10-13 Ovid Therapeutics Inc. USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS
CA3120856A1 (en) * 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
CA3123876A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US20210015760A1 (en) * 2019-07-15 2021-01-21 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
EP4051272A4 (en) 2019-12-18 2023-01-04 Ovid Therapeutics Inc. GABOXADOL FOR THE THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
JP2023526439A (ja) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド 精神障害の処置のための環重水素化ガボキサドールおよびその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
EP3151832B1 (en) 2014-06-06 2021-03-24 Ovid Therapeutics, Inc. Methods of increasing tonic inhibition and treating secondary insomnia
CA2992734A1 (en) * 2015-07-17 2017-01-26 Ovid Therapeutics, Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
LT3151832T (lt) 2021-07-12
EP3151832A4 (en) 2018-01-17
AU2024202604A1 (en) 2024-05-09
IL249287B (en) 2021-03-25
ES2875742T3 (es) 2021-11-11
HUE055155T2 (hu) 2021-11-29
US20170071917A1 (en) 2017-03-16
US20150352085A1 (en) 2015-12-10
US9339495B2 (en) 2016-05-17
SI3151832T1 (sl) 2021-08-31
AR100772A1 (es) 2016-11-02
PT3372229T (pt) 2021-06-17
HRP20210902T1 (hr) 2021-09-17
US20220016091A1 (en) 2022-01-20
WO2015187851A1 (en) 2015-12-10
ES2876350T3 (es) 2021-11-12
EP3151832B1 (en) 2021-03-24
US20230051859A1 (en) 2023-02-16
DK3372229T3 (da) 2021-06-14
MX2016016136A (es) 2017-07-05
JP2017516868A (ja) 2017-06-22
EP3372229A1 (en) 2018-09-12
US20170273956A1 (en) 2017-09-28
US20180303805A1 (en) 2018-10-25
JP2021178836A (ja) 2021-11-18
EP3151832A1 (en) 2017-04-12
US20160038469A1 (en) 2016-02-11
US9446028B2 (en) 2016-09-20
US9801864B2 (en) 2017-10-31
LT3372229T (lt) 2021-07-12
DK3151832T3 (da) 2021-06-14
US20160228418A1 (en) 2016-08-11
MX2020012404A (es) 2022-04-11
RS62007B1 (sr) 2021-07-30
EP3372229B1 (en) 2021-03-24
US20170087133A1 (en) 2017-03-30
EP3795156A1 (en) 2021-03-24
US9744159B2 (en) 2017-08-29
PL3151832T3 (pl) 2021-10-25
US20180015076A1 (en) 2018-01-18
PT3151832T (pt) 2021-06-15
IL268960B (en) 2021-05-31
HUE055400T2 (hu) 2021-11-29
CA2950845A1 (en) 2015-12-10
US11278529B2 (en) 2022-03-22
RS62006B1 (sr) 2021-07-30
JP2020063264A (ja) 2020-04-23
CY1124366T1 (el) 2022-07-22
CY1124368T1 (el) 2022-07-22
CA2950845C (en) 2023-04-25
AU2022200085A1 (en) 2022-02-03
IL249287A0 (en) 2017-02-28
AU2015269667B2 (en) 2020-07-30
AU2020217342A1 (en) 2020-08-27
HRP20210901T1 (hr) 2021-09-17
SI3372229T1 (sl) 2021-09-30
JP2023123442A (ja) 2023-09-05
AU2015269667A1 (en) 2016-12-22
AU2020217342B2 (en) 2021-10-07
IL268960A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
RS62007B1 (sr) Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
IL250415B (en) Antibodies against pd-l and methods of using them
HK1253049A1 (zh) 糖基相互作用化合物及其使用方法
IL259801A (en) ezh2 inhibitors and methods of using them
IL282482A (en) Variants of protoxin-II and methods of use
HK1254954A1 (zh) Lpt-723和免疫檢查點抑制劑組合物及其治療方法
GB201514760D0 (en) Compounds and method of use
IL282508A (en) Variants of protoxin-II and methods of use
GB201416832D0 (en) Methods of treatment
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201511799D0 (en) Composition and methods of treatment
HK1243961A1 (zh) 炎性病况的預防和治療
GB201520900D0 (en) Devices and methods for treatment of ventilator associated dysphagia
GB201417248D0 (en) Compostion and methods of treatment
HUE058190T2 (hu) Enoláz inhibitorok és ezekkel történõ kezelési eljárások
GB201512139D0 (en) Methods of treatment
GB201416797D0 (en) Contianer and method of use thereof